Antibody Information
General Information of This Antibody
| Antibody ID | ANI0JGWSI |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | SHR-2495 |
|||||
| Organization | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
|||||
| Synonyms |
SHR-2495
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antigen Name | Delta-like protein 3 (DLL3) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SHR-4849 [Phase 2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible subjects were 18-75 years with advanced solid tumors (measurable per RECIST 1.1), ECOG 0-1, life expectancy ≥3 months, and adequate organ function. Key exclusions: CNS metastasis, recent malignancies (5 years), uncontrolled pain/effusions, severe CVD/interstitial lung disease, active HBV/HCV/HIV, unresolved prior toxicities (CTCAE >Grade 1), recent anticancer therapy/surgery (4 weeks), pregnancy, or drug allergies. Additional exclusions per investigator discretion.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06443489 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I ,Open-label, Multicenter Clinical Study to Evaluate the Safety, Tolerability , Pharmacokinetics and Efficacy of SHR-4849 in Patients With Advanced Solid Tumors
|
||||
| Primary Endpoint |
The study assessed dose-limiting toxicities (DLTs) during a 21-day observation period post-dosing, along with AEs/SAEs graded per NCI-CTCAE v5.0 monitored for 24 months. The MTD/MAD and RP2D were determined after subjects in escalation/expansion phases completed ≥1 dosing cycle (24-month follow-up).
|
||||
| Other Endpoint |
Efficacy outcomes included ORR (CR+PR), DCR (CR+PR+SD), DoR (time to progression/death), and PFS (treatment-initiation to progression/death)-all per RECIST 1.1 over 24 months-plus OS (30-month follow-up from treatment initiation).
|
||||